Solid Biosciences Inc./$SLDB
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Solid Biosciences Inc.
Solid Biosciences Inc is a life science company. It is engaged in the manufacturing of specialty and generic drugs. The company is involved in curing Duchenne muscular dystrophy (DMD), a genetic muscle-wasting disease predominantly affecting boys, with symptoms that usually manifest between three and five years of age. The company's pipeline products are the SB-001 and solid suit. The Company's singular focus is on developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases. The company has categorized its programs into corrective therapies, disease-modifying therapies, and assistive devices.
Ticker
$SLDB
Sector
Primary listing
Employees
100
Headquarters
Website
SLDB Metrics
BasicAdvanced
$438M
-
-$2.52
2.44
-
Price and volume
Market cap
$438M
Beta
2.44
52-week high
$7.37
52-week low
$2.41
Average daily volume
1.2M
Financial strength
Current ratio
9.336
Quick ratio
8.983
Long term debt to equity
7.803
Total debt to equity
8.924
Interest coverage (TTM)
-550.26%
Profitability
EBITDA (TTM)
-155.137
Management effectiveness
Return on assets (TTM)
-36.35%
Return on equity (TTM)
-68.25%
Valuation
Price to book
1.69
Price to tangible book (TTM)
1.69
Price to free cash flow (TTM)
-2.789
Free cash flow yield (TTM)
-35.86%
Free cash flow per share (TTM)
-2.015
Growth
Earnings per share change (TTM)
-17.14%
3-year earnings per share growth (CAGR)
-39.94%
Bulls say / Bears say
The company ended Q2 2025 with $268.1 million in cash and equivalents, securing operational runway into the first half of 2027. (Reuters)
Solid anticipates initiating Phase 1b trials for SGT-212 (Friedreich’s ataxia) and SGT-501 (CPVT) in Q4 2025, demonstrating pipeline diversification beyond Duchenne. (Reuters)
A planned FDA meeting in Q4 2025 to discuss potential accelerated approval pathways for SGT-003 reflects proactive regulatory engagement aimed at expediting commercialization. (Reuters)
Q2 net loss widened to $39.5 million in Q2 2025, up from $25.1 million in Q2 2024, highlighting accelerating financial losses for the company. (Reuters)
Research and development expenses surged to $32.4 million in Q2 2025, a 66.7% year-over-year increase driven by manufacturing, regulatory, and clinical costs for SGT-003, exacerbating the company’s cash burn. (Reuters)
Regulatory clarity for SGT-003 remains pending, with planned FDA discussions not scheduled until Q4 2025, delaying potential approval and commercialization timelines. (Reuters)
Data summarised monthly by Lightyear AI. Last updated on 4 Oct 2025.
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Solid Biosciences Inc. stock?
Solid Biosciences Inc. (SLDB) has a market cap of $438M as of October 25, 2025.
What is the P/E ratio for Solid Biosciences Inc. stock?
The price to earnings (P/E) ratio for Solid Biosciences Inc. (SLDB) stock is 0 as of October 25, 2025.
Does Solid Biosciences Inc. stock pay dividends?
No, Solid Biosciences Inc. (SLDB) stock does not pay dividends to its shareholders as of October 25, 2025.
When is the next Solid Biosciences Inc. dividend payment date?
Solid Biosciences Inc. (SLDB) stock does not pay dividends to its shareholders.
What is the beta indicator for Solid Biosciences Inc.?
Solid Biosciences Inc. (SLDB) has a beta rating of 2.44. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.